FDA cleared CTA for LILRB4/CD3 targeting TCE bispecific antibody (6MW5311) for the treatment of AML, CMML, and Multiple Myeloma June 17, 2026
Solu Therapeutics Closes $41M Series A Financing; First Patient Dosed in Ph 1 Trial of STX-0712 in Patients with CMML and Other Heme Malignancies April 16, 2025
Ph 1/2 dose-escalation study of SP-2577 in combination with azacitidine in adults with MDS and CMML Placed on Partial Hold July 17, 2024
Orphan Drug Designation Granted by US FDA for IO-202 (Anti-LILRB4) for the Treatment of Chronic Myelomonocytic Leukemia (CMML) February 26, 2024
